FBS, in 96-well plates. After 24 h, various concentrations of different materials were added. After 24, 72 and 144 h, 20 ml of an MTS (3- [4,5- 
dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) solution (CellTiter 96
® Aqueous One Solution Cell Proliferation Assay, Promega) was added and the plates were incubated for further 1-4 h. The optical density at 490 nm was measured with a 96-well plate reader, as the quantity of formazan produced, as measured by the absorbance at 490 nm, is directly proportional to the number of living cells in the culture. Concentration for 50% inhibition (IC 50 ) values were obtained via nonlinear regression of concentration-response curves.
Fatty Acid Synthase (FAS) in Vitro Assay The cells were harvested and the pellets collected by centrifugation. The resulting pellets were then resuspended in a hypotonic buffer (pHϭ7.5) consisting of 1 mM EDTA and 20 mM Tris-HCl. The sample protein contents were measured using a BCA assay kit (Pierce). 50 mg protein, various concentrations of drugs and 20 ml of the reaction mixture were then added to tubes containing 2.5 ml of a potassium phosphate buffer (100 mM, pHϭ7). The reaction mixture consisted of 2.5 mM NADPH, 1.25 mM acetyl-CoA, 1.25 mM MalonylCoA and 0.02 mM [2- Measurement of Vascular Endothelial Growth Factor (VEGF) and Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF) After trypsinization process, 3ϫ10 6 cells were placed in the assay wells of culture dishes contaning 1 ml of complete RPMI (Falcon multiwell 12 wells, Becton Dickinson Labware, U.S.A.). Then, cells were treated with 10 Ϫ6 M concentration of apigenin, fisetin and diazepam for 6 d, respectively. Human vascular endothelial growth factor kit (VEGF Immunoassay, Koma-biotech, Korea) and human granulocyte-macrophage-colony stimulating factor kit (GM-CSF Immunoassay, Komabiotech, Korea) were used to measure VEGF and GM-CSF concentration, respectively. The optical density of each sample was measured in microplate reader at 450 nm. Release amounts of VEGF and GM-CSF were normalized by viable cell counts in each well.
Statistical Analysis The data represent the meanϮthe standard error (S.E.). Inter-group data comparisions were made using Student's t-test (Systat, Intelligent Software, Evanston, IL, U.S.A.). Nonlinear regression for obtaining the IC 50 value were made using computer software (Prism, Graphpad, U.S.A.).
RESULTS
As shown in Fig. 1 , treatment for 72 h with apigenin and fisetin, both flavonoids showed concentration-dependent inhibition on the survival of the SNU-C4 and MDA-MB-231 adenocarcinoma cells. In the SNU-C4 cells, IC 50 (mM) of apigenin-and fisetin-treated group was 2.3Ϯ0.2 and 0.8Ϯ0.1, respectively. In the MDA-MB-231 cells, IC 50 (mM) of apigenin-and fisetin-treated group was 1.2Ϯ0.3 and 3.2Ϯ0.5, respectively. Same treatment of diazepam, a synthetic benzodiazepine, showed also cancer cell survival concentration-dependently. IC 50 (mM) of diazepam-treated group was 5.5Ϯ1.2 and 0.12Ϯ0.1, in the SNU-C4 and MDA-MB-231 adenocarcinoma cells, respectively.
As shown in Fig. 2 , in the longer duration of treatment, micromolar concentration of apigenin and fisetin showed the higher inhibitory effect on the survival of the SNU-C4 and MDA-MB-231 adenocarcinoma cells. Like flavonoids, 10 Ϫ6 M concentration of diazepam, also showed incubation time-dependent inhibition of the cell survival. In the group treated for 72 h with the same concentration of apigenin, fisetin and diazepam, inhibition of cell survival (%) were increased to 10.3Ϯ1.0, 8.8Ϯ0.9 and 8.9Ϯ1.2, respectively. In the group treated for 144 h with the same concentration of apigenin, fisetin and diazepam, inhibition of cell survival (%) were increased to 9.2Ϯ1.2, 10.9Ϯ2.1 and 9.6Ϯ0.6, respectively.
As shown in 2.3Ϯ0.1 in the SNU-C4 and MDA-MB-231 cancer cells, respectively.
As shown in Fig. 4 , concentration-dependent inhibitory effect on FAS activity, known as an anticancer mechanism of flavonoids, was also observed in the various concentrations (10 Ϫ5 M, 10 Ϫ6 M, 10 Ϫ7 M, 10 Ϫ8 M) of the sedative-treated (for 30 min) SNU-C4 and MDA-MB-231 cancer cells. In the apigenin, fisetin and diazepam-treated groups, IC 50 (mM) were 3.9Ϯ0.6, 1.0Ϯ0.2, and 5.4Ϯ0.4, respectively for the SNU-C4 cells, and 0.6Ϯ0.1, 4.7Ϯ0.6, and 2.4Ϯ0.3, respectively for the MDA-MB-231 cancer cells.
As shown in Fig. 5 , for the SNU-C4 and MDA-MB-231 adenocarcinoma cells, anticancer cytotoxicity induced by flavonoids or diazepam was not reduced by treatment of 10 Ϫ6 M concentration of 5-fluorouracil (5-FU), a chemotherapeutic agent. Their inhibitory action on cancer cell survivals was further enhanced by the addition of PK11195, a putative chemosensitizer.
As shown in Fig. 6 , treatment of micromolar concentration of apigenin and fisetin reduced the release of VEGF, and examined flavonoids also reduced the release of GM-CSF from the SNU-C4 and MDA-MB-231 adenocarcinoma cells. In this study, like flavonoids, micromolar concentration of diazepam inhibited the release of VEGF and GM-CSF into supernatants of cultured SNU-C4 and MDA-MB-231 adenocarcinoma cells.
DISCUSSION
Flavonoids, as polyphenolic compounds found in plants, have already been reported to have anti-cancer efficacies. [17] [18] [19] Consistently, in this study, apigenin and fisetin, flavonoids showed in vitro anticancer cytotoxicity. Like flavonoids, diazepam, a sedative also showed inhibition of cancer cell survival. The anticancer cytotoxicity of flavonoids and diazepam showed the concentration-dependency, and micromolar ranges of IC 50 . The plasma concentration of diazepam in patients who are taking therapeutic dose of diazepam (5-10 mg) were found to be micromolar range. The inhibition of FAS activity, is a known cytotoxic mechanism of flavonoids, 20) and in the present study, micromolar concentration of diazepam consistently inhibited the FAS activity in the SNU-C4 and MDA-MB-231 cells.
In highly aggressive breast cancer cells, such as MDA-MB-231 cells, a nuclear/perinuclear located PBR have been reported to mediate the stimulation of cancer cell survival. 15, 16) Consistently, in this study, PK11195, a specific PBR ligand remarkebly enhanced the proliferation of MDA-MB-231 breast adenocarcinoma cells, but diazepam reduced the cell survival. However, PBR as a critical part of the mitochondrial permeability transition pore (mPT) has been shown to mediate enhancing the apoptosis. [9] [10] [11] [12] [13] [14] In a previous study by the current authors, 21) anticancer cytotoxic flavonoids including apigenin elicited up-regulation of PBR mRNA expression in SK-N-Mc human neuroblastoma cells. Moreover, in this study, treatment with PBR ligands consistently inhibited the SNU-C4 cell survival, and diazepam also produced anticancer cytotoxic effects, similar to those caused by flavonoids.
In highly aggressive cancer cells, including MDA-MB-231 breast cancer cells, an increased cholesterol influx into the nucleus has been reported to be associated with the proliferative action of a perinuclear/nuclear located PBR.
16) Consistent with this, in the present study, proliferative effect of PK11195 on of the MDA-MB-231 cells was reversed by the co-administration of lovastatin, a HMG-CoA reductase inhibitor. HMG-CoA reductase is an enzyme that catalyzes the rate-limiting step of the isoprenoid producing mevalonate pathway, and isoprenoid is involved in the activation of Ras and cholesterol synthesis. In particular, lipid soluble statins have been also shown to produce antitumor effects, and reduce intracellular cholesterol level. [22] [23] [24] In the present study, single treatment of lovastatin showed weak anticancer cell cytotoxicity. Moreover, the micromolar concentration of diazepam-and flavonoids-induced cytotoxic activity in the cancer cells in this study was not reduced by the addition of 5-fluorouracil (5-FU), a chemotherapeutic agent. PK11195 has been reported to generate a reversal action on the chemoresistance in cancer cells, independent of the direct activation of PBR. [25] [26] [27] In this study, PK11195, a putative chemosensitizer, showed further enhancement of their anticancer effects.
VEGF and GM-CSF were shown to stimulate malignant tumor cell growth and migration in vitro and to promote cancer progression in vivo. 28, 29) Modulation of angiogenesis via VEGF system by black tea polyphenols has been proposed as a mechanism of chemopreventon of rat mammary carcinogenesis. 29) Flavonoids, active ingredients isolated from several plants, have been also introduced to inhibit tumor angiogenesis through decreasing VEGF expression and the release of the angiogenic peptide VEGF from U-343 and U-118 human glioma cells. 30, 31) Consistently with these, treatment of micromolar concentration of apigenin and fisetin reduced the release of VEGF, and examined flavonoids also reduced the release of GM-CSF from in the SNU-C4 and MDA-MB-231 cells. In this study, micromolar concentration of diazepam inhibit the release of VEGF and GM-CSF like flavonoids into supernatants of cultured in the SNU-C4 and MDA-MB-231 cells.
In cancer cells, increased glucose transporter (Glut) and hexokinase (HK) activities facilitate glucose utilization and thus continuous intracellular accumulation of fluoro-deoxyglucose (FDG). The logic behind delayed FDG PET imaging is based on the known fact that most types of malignant cells have significantly increased ratios of HK to glucose-6-phosphatase activities, which allow 18F-deoxyglucose-6-phosphatate to accumulate to a much higher level over time than in the normal cells. It has been reported that the routine use of 5 mg diazepam p.o. before intravenous administration of FDG renders PET imaging ineffective.
32) It has also been reported that diazepam inhibit the function of Glut, insulin sensitivity and HK activity. 33, 34) From above reports, it can be postulated that sedative may elicit in vivo anticancer efficacy.
Agents that inhibit glucose uptake should decrease the proliferation of cancer cells. Certain flavonoids inhibit glucose uptake in culture cells. 35, 36) Flavonoids, polyphnolic compounds distributed widely in plant-based foods, exert diverse biological effects in cultured cells and in vivo. Certain flavonoids including apigenin have been reported to show a selective anxiolysis in mice (10 mg/kg i.p.), and a partial agonistic activity at the CBRs in micromolar concentration. 37) In the plasma samples of population taking apigenin-rich foods regularly, similar amounts of the compound were detected. Yet, the difficulties involved with attaining a sufficient concentration to activate the central nervous system present an obstacle. Therefore, the improved activities shown by certain synthetic derivatives, such as methylapigenin, may provide a better challenge. Moreover, caffeic acid butyl ester and various related synthetic nitroflavone derivatives have exhibited potent anticancer activity, without affecting normal cell survival. 38) Consistently, these options may support a safer use of sedative in the management of oncologic patients. Plus compounds derived from natural products have been shown to be advantageous over synthetic sedatives, due to diminished adverse effects, such as muscle relaxation, tolerance, and dependency.
The results of our study can increase the knowledge about the influence of the examined substances on proliferation and progression of cancer cells. Our observations might give an insight into the safe use of sedatives in the malignancies. However, for a prolonged use, natural substance like apigenin might be advantageous over a synthetic drugs. In conclusion, this study provided in vitro information on the use of flavonoids and sedative in oncologic patients.
